Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., Hanefeld, M.·2014·Diabetic Medicine
DOI 10.1111/dme.12328

Cited by (144)

Items 101–144 of 144

  1. The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials
    Lei Sheng, Meixian Deng, Xin Li, Huan Ying Wan, Changjiang Lei, Kousalya Prabahar, Benjamin Hernández‐Wolters, Hamed Kord‐Varkaneh · 2024 · Diabetes Research and Clinical Practice
  2. Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
    Miles Fisher · 2014 · Diabetes Obesity and Metabolism
  3. Safety, tolerability and efficacy of lixisenatide as monotherapy in Japanese patients with type 2 diabetes mellitus: An open‐label, multicenter study
    Yutaka Seino, Yasuo Terauchi, Xiangling Wang, Daisuke Watanabe, Elisabeth Niemoeller, the study investigators · 2017 · Journal of Diabetes Investigation
  4. A systematic review of the safety of incretin-based therapies in type 2 diabetes
    Marc Evans, Stephen Charles Bain, Jiten P Vora · 2016 · Expert Review of Endocrinology & Metabolism
  5. Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring
    Richard M. Bergenstal, Ellie S. Strock, Roger S. Mazze, Margaret A. Powers, Arlene M. Monk, Sara A. Richter, Elisabeth Souhami, Bo Åhrén · 2016 · Diabetes/Metabolism Research and Reviews
  6. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model
    Shuai Yuan, Yingyu Wu · 2023 · Frontiers in Public Health
  7. Treatment with GLP-1 Receptor Agonists
    Sten Madsbad, Jens Juul Holst · 2018 · Endocrinology
  8. Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis
    Sanaz Kamalinia, Robert G. Josse, Patrick J. Donio, Lindsay Leduc, Baiju R. Shah, Sheldon W. Tobe · 2019 · Endocrinology Diabetes & Metabolism
  9. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
    Lora Petrova, Kalina Andreevska, Iva Parvova, Valentina Boyanova Petkova · 2024 · Pharmacia
  10. Lixisenatide
    Danial E. Baker, Terri L. Levien · 2017 · Hospital Pharmacy
  11. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies
    Adil Farooq Wali, Imran Rashid Rangraze, Shehla Shafi Khan, Uwais Mufti, Mohamed El‐Tanani, Manfredi Rizzo · 2026 · Frontiers in Pharmacology
  12. Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta‐analysis from the GetGoal programme
    Fabio Broglio, Edoardo Mannucci, Raffaele Napoli, Antonio Nicolucci, Francesco Purrello, Elena Nikonova, William Stager, Roberto Trevisan · 2016 · Diabetes Obesity and Metabolism
  13. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
    Luis Peña Icart, Fernando Gomes de Souza, Luís Maurício T. R. Lima · 2021 · Journal of Microencapsulation
  14. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study
    Yasuo Terauchi, Makiko Usami, Tomoyuki Inoue · 2022 · Advances in Therapy
  15. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care
    Zin Zin Htike, Francesco Zaccardi, Sudesna Chatterjee, Kamlesh Khunti, Melanie Jane Davies · 2016 · British Journal of Diabetes
  16. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in dermatology: cutaneous adverse events and emerging efficacy in inflammatory skin diseases
    Meng Jie Ho, Choon Fong Liew, N A Muhammad Ridzuan Tan, Akimichi Morita, Hazel Hwee Boon Oon · 2026 · Expert Review of Clinical Immunology
  17. Safety, tolerability and efficacy of lixisenatide in combination with oral antidiabetic treatment in Japanese patients with type 2 diabetes: An open‐label, multicenter study
    Yutaka Seino, Aleksandra Stjepanovic, Akane Takami, Hiroki Takagi, the study investigators · 2017 · Journal of Diabetes Investigation
  18. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus
    Ronnie Aronson · 2013 · Expert Review of Clinical Pharmacology
  19. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
    M Hanefeld, D. Raccah, Louis Monnier · 2016 · Expert Opinion on Drug Metabolism & Toxicology
  20. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
    Agata Schubert, Anders T. Buchholt, Antoine C. El Khoury, Ahmed Kamal, V. Taieb · 2017 · Current Medical Research and Opinion
  21. Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Yufeng Rao, Shiqiu Meng, Evan Yi-Wen Yu, Yiming Chen, Remigius van Alebeek, Abdulmohsen Hamdan Al-Zalabani, Maurice Petrus Zeegers, Anke Wesselius · 2025 · Endocrine Practice
  22. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis
    Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli · 2026 · Pancreatology
  23. WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Julie A. Lovshin · 2017 · Canadian Journal of Diabetes · Retracted
  24. Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
    Mohamad Sirri Tarazi, Samir Touhamy, Beverly G. Tchang, Alpana P. Shukla · 2021 · Expert Opinion on Pharmacotherapy
  25. PRISMA—efficacy and safety of lixisenatide for type 2 diabetes mellitus
    Zhengang Wei, Mancai Wang, Huihan Zhang, Zheyuan Wang, Gen-nian Wang, Fengxian Wei, Yawu Zhang, Xiaodong Xu, Youcheng Zhang · 2018 · Medicine
  26. Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update
    Eun Ju Lee, Tae Nyun Kim · 2016 · The Korean Journal of Obesity
  27. Real-World Effectiveness and Safety of Lixisenatide as Add-On to Oral Antidiabetic Drugs as Part of Routine Clinical Practice in Bulgaria: LIXODAR Study
    Nataliya Temelkova, Stefka V. Vladeva, Aleksi Delchev, Kalina Ivanova, Yoanna Gerasimova-Zheleva, Tsvetodara Kuneva, Veselina Pehlivanova, Plamen R. Popivanov · 2019 · Diabetes Therapy
  28. Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
    Shuzhen Bai, Chu Lin, Ruoyang Jiao, Xiaoling Cai, Suiyuan Hu, Fang Lv, Wenjia Yang, Xingyun Zhu, Linong Ji · 2023 · European Journal of Internal Medicine
  29. Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
    Katherine Ann Lyseng-Williamson, Lesley J. Scott · 2013 · Drugs & Therapy Perspectives
  30. Pharmacologic Approach to Type 2 Diabetes in Obese Patients
    León Litwak, Carla Musso, Susana Fuentes · 2014 · Springer eBooks
  31. Lixisenatide: A New Glucagon-Like Peptide-1 Agonist
    Christopher W. Ho · 2013 · Journal of Developing Drugs
  32. New Therapeutic Approaches to Prevent or Delay Beta-Cell Failure in Diabetes
    Floriana Elvira Ionică · 2015 · Romanian Journal of Diabetes Nutrition and Metabolic Diseases
  33. Lixisenatide: a once-daily glucagon-like peptide-1 receptor agonist
    Tushar B. Chudiwal, Indrajeet Sharma · 2016 · International Journal of Basic & Clinical Pharmacology
  34. Non‐Insulin Parenteral Therapies
    Tina Vilsbøll, Mikkel Christensen, Tina Jorsal, Filip Krag Knop · 2016
  35. Treatment with GLP-1 Receptor Agonists
    Sten Madsbad, Jens Juul Holst · 2018 · Endocrinology
  36. Type 2 diabetes: glycaemic control
    David Levy MD FRCP · 2017 · Wiley eBooks
  37. Faculty Opinions recommendation of Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Stefan G. De Hert · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  38. Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
    Michael Albrecht Nauck · 2023 · Deutsches Ärzteblatt
  39. Non‐insulin Parenteral Therapies
    Tina Vilsbøll, Mikkel Christensen, Andreas Andersen, Filip Krag Knop · 2024 · Wiley eBooks
  40. Additional file 1 of Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
    Lin Chu, Cai, Xiaoling, Yang, Wenjia, Lv, Fang, Nie, Lin, Ji, Linong · 2020 · Figshare
  41. Glucagon-like Peptide-1 Receptor Agonists and Risk of Thyroid Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Dena Osama Khawandanah, Faris F. Alyamani, Bader R. Almutairi, Basil A. Almutairi, Reham Mohammed Alharbi, Shahad Alghanmi, Mohammed T. Alsouri, ABDULAALI R. ALMUTAIRI · 2025 · Saudi Journal of Clinical Pharmacy
  42. The effect of GLP-1 receptor agonists on osteoarthritis risk in individuals with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized controlled trials
    Limin Zhou, Peiyang Wu, Yongxiang Xu, Baocheng Xie · 2026 · Acta Diabetologica
  43. Comparative cardiovascular efficacy of antidiabetic therapies in type 2 diabetes: a systematic review and network meta-analysis of randomized trials
    Donya Mohammadi, Behnam Sadeghirad, Mohammad Aziz Rasouli, Lotfollah Saed, Hamid Reza Baradaran, Yousef Moradi · 2026 · Diabetology & Metabolic Syndrome
  44. GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
    Elena Koceva, Gert N. Moll · 2026 · European Journal of Pharmacology